{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:25:54Z","timestamp":1783416354643,"version":"3.54.6"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,22]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study investigated the possible association between nicorandil and gastrointestinal adverse events using the FDA Adverse Event Reporting System (FAERS), aiming to provide more comprehensive safety guidance for clinical application and support the formulation of pharmacovigilance policies in the future. This study is a retrospective study based on FAERS. Adverse event reports in FAERS from the first quarter of 2016 to the fourth quarter of 2023 were extracted. Disproportionality analyses were employed to assess the association between nicorandil and gastrointestinal adverse events, and to conduct a further analysis of clinical characteristics. We also performed sensitivity analyses stratified by gender and age. A total of 138 reports of nicorandil-related gastrointestinal adverse events were retrieved from FAERS, with a large proportion of elderly patients (aged\u2005&gt;\u200565 years, n\u2005=\u200598). The results of the disproportionality analysis indicated an elevated risk of gastrointestinal adverse events associated with nicorandil (reporting odds ratio:1.23, 95% CI: 1.09\u20131.39; information component\n                      <jats:sub>025<\/jats:sub>\n                      \u2005=\u20052.43). Clinical prioritization analysis identified melaena, colonic polyp, and upper gastrointestinal bleeding as events of moderate clinical priority. Most gastrointestinal adverse events tend to occur within 1 week after the initiation of dosing. Sensitivity analyses revealed that nicorandil was significantly associated with gastrointestinal adverse events regardless of gender and age. The use of nicorandil was significantly associated with gastrointestinal adverse events. This study assists healthcare professionals in providing appropriate guidance and advice to patients prior to drug administration.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048762","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:01:50Z","timestamp":1779469310000},"page":"e48762","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective analysis of gastrointestinal adverse events associated with nicorandil using the FDA Adverse Event Reporting System (FAERS) following STROBE guidelines"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3918-2520","authenticated-orcid":false,"given":"Chen","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Nursing, Pingdingshan University, Pingdingshan, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2171-1848","authenticated-orcid":false,"given":"Daying","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary, Pancreatic and Splenic Surgery, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture (Enshi Clinical College of Wuhan University), Enshi, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4838-2709","authenticated-orcid":false,"given":"Yunhong","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Academic, Yichang Hubo Medical Research Institute, Yichang, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8868-9193","authenticated-orcid":false,"given":"Luhuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Academic, Yichang Hubo Medical Research Institute, Yichang, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Academic, Yichang Hubo Medical Research Institute, Yichang, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260707","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2018.09.086","article-title":"Multitarget strategies to reduce myocardial ischemia\/reperfusion injury: JACC review topic of the week.","volume":"73","author":"Davidson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R2-20260707","doi-asserted-by":"crossref","first-page":"10742484231197559","DOI":"10.1177\/10742484231197559","article-title":"Combination of nicorandil and beta-adrenergic receptor blockers in patients with coronary artery disease: a real-world observational study.","volume":"28","author":"Cheng","year":"2023","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R3-20260707","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s12325-020-01582-w","article-title":"The role of nicorandil in the management of chronic coronary syndromes in the Gulf Region.","volume":"38","author":"Cheng","year":"2021","journal-title":"Adv Ther"},{"key":"R5-20260707","doi-asserted-by":"crossref","first-page":"adv41006","DOI":"10.2340\/actadv.v104.41006","article-title":"Spontaneous mucocutaneous ulcerations: a quiz.","volume":"104","author":"Drivenes","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"R6-20260707","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7748\/en.22.5.12.s13","article-title":"Martindale: the complete drug reference Brayfield Alison (Ed) Martindale: the complete drug reference \u00a3459 4,688pp Pharmaceutical Press 9780857111395 0857111396 [formula: see text].","volume":"22","year":"2014","journal-title":"Emerg Nurse"},{"key":"R7-20260707","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12325-016-0294-9","article-title":"Nicorandil, gastrointestinal adverse drug reactions and ulcerations: a systematic review.","volume":"33","author":"Pisano","year":"2016","journal-title":"Adv Ther"},{"key":"R8-20260707","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/cpt.1941","article-title":"Genetic risk of diverticular disease predicts early stoppage of nicorandil.","volume":"108","author":"Noyes","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"R9-20260707","article-title":"Risque d\u2019ulc\u00e9rations cutan\u00e9o-muqueuses li\u00e9 au nicorandil: donn\u00e9es r\u00e9centes de la base nationale de pharmacovigilance fran\u00e7aise et du programme de m\u00e9dicalisation des syst\u00e8mes d\u2019information (NICORUC) [Risk of mucocutaneous ulcerations associated with nicorandil: recent data of the French Pharmacovigilance DataBase and Toulouse Hospital Discharge DataBase (NICORUC)] [published online ahead of print September 5, 2025].","author":"Batty","journal-title":"Therapie"},{"key":"R10-20260707","doi-asserted-by":"crossref","first-page":"1378010","DOI":"10.3389\/fphar.2024.1378010","article-title":"Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database.","volume":"15","author":"Long","year":"2024","journal-title":"Front Pharmacol"},{"key":"R11-20260707","doi-asserted-by":"crossref","first-page":"817662","DOI":"10.3389\/fphar.2022.817662","article-title":"Pancreatic adverse events associated with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis.","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R12-20260707","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1111\/cns.14215","article-title":"Cardiac adverse events associated with quetiapine: disproportionality analysis of FDA adverse event reporting system.","volume":"29","author":"Shu","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"R13-20260707","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","article-title":"Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures.","volume":"15","author":"Ang","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"R14-20260707","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1177\/1352458520949986","article-title":"Adverse event profile differences between rituximab and ocrelizumab: findings from the FDA Adverse Event Reporting Database.","volume":"27","author":"Caldito","year":"2021","journal-title":"Mult Scler"},{"key":"R15-20260707","doi-asserted-by":"crossref","first-page":"1075966","DOI":"10.3389\/fphar.2022.1075966","article-title":"Corrigendum: Neurological adverse events associated with esketamine: a disproportionality analysis for signal detection leveraging the FDA adverse event reporting system.","volume":"13","author":"Guo","year":"2022","journal-title":"Front Pharmacol"},{"key":"R16-20260707","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40360-023-00702-w","article-title":"A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).","volume":"24","author":"Zou","year":"2023","journal-title":"BMC Pharmacol Toxicol"},{"key":"R17-20260707","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/14712598.2021.1948529","article-title":"The impact of anti-TNF\u03b1 agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database.","volume":"21","author":"Mazhar","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"R18-20260707","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction.","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"R19-20260707","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/heartjnl-2023-322345","article-title":"Prevalence of angina pectoris and association with coronary atherosclerosis in a general population.","volume":"109","author":"Wel\u00e9n Schef","year":"2023","journal-title":"Heart"},{"key":"R20-20260707","first-page":"CD012419","article-title":"Interventions for improving medication-taking ability and adherence in older adults prescribed multiple medications.","volume":"5","author":"Cross","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R21-20260707","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(02)08265-X","article-title":"Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.","volume":"359","year":"2002","journal-title":"Lancet"},{"key":"R22-20260707","article-title":"Letter to editor: nicorandil: a word of caution on growing long-term risks versus benefits","author":"Khan","journal-title":"Int Urol Nephrol"},{"key":"R23-20260707","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12576-024-00916-5","article-title":"Purinergic inhibitory regulation of esophageal smooth muscle is mediated by P2Y receptors and ATP-dependent potassium channels in rats.","volume":"74","author":"Shiina","year":"2024","journal-title":"J Physiol Sci"},{"key":"R24-20260707","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.3390\/ijms25126467","article-title":"Dynamic changes in ion channels during myocardial infarction and therapeutic challenges.","volume":"25","author":"Song","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R25-20260707","doi-asserted-by":"crossref","first-page":"625","DOI":"10.5937\/arhfarm74-51604","article-title":"KATP channels and cardioprotection.","volume":"74","author":"Taskin","year":"2024","journal-title":"Arh Farm (Belgr)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:01:49Z","timestamp":1783414909000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":24,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048762","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2025-08-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}